Hertzel C Gerstein

List of Publications by Year
in descending order

454	71,851	1530 106	601 260
papers	citations	h-index	g-index

474	474	474	47005
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine, 2008, 358, 2545-2559.	13.9	7,084
2	Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet, The, 2000, 355, 253-259.	6.3	3,134
3	Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. New England Journal of Medicine, 2010, 362, 1575-1585.	13.9	3,117
4	Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. New England Journal of Medicine, 2010, 362, 1563-1574.	13.9	2,460
5	Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals. JAMA - Journal of the American Medical Association, 2001, 286, 421.	3.8	2,067
6	Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet, The, 2000, 355, 773-778.	6.3	1,959
7	Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine, 2015, 373, 2247-2257.	13.9	1,856
8	Users' Guides to the Medical Literature. JAMA - Journal of the American Medical Association, 1994, 271, 703.	3.8	1,710
9	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, The, 2019, 394, 121-130.	6.3	1,625
10	Stress Hyperglycemia and Prognosis of Stroke in Nondiabetic and Diabetic Patients. Stroke, 2001, 32, 2426-2432.	1.0	1,609
11	The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care, 1999, 22, 233-240.	4.3	1,571
12	Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet, The, 2006, 368, 1096-1105.	6.3	1,564
13	Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine, 2012, 367, 319-328.	13.9	1,426
14	Renal Insufficiency as a Predictor of Cardiovascular Outcomes and the Impact of Ramipril: The HOPE Randomized Trial. Annals of Internal Medicine, 2001, 134, 629.	2.0	1,243
15	Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. New England Journal of Medicine, 2010, 363, 233-244.	13.9	1,091
16	Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia, 2009, 52, 2288-2298.	2.9	1,033
17	Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes. New England Journal of Medicine, 2011, 364, 818-828.	13.9	901
18	Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet, The, 2000, 356, 279-284.	6.3	866

#	Article	IF	Citations
19	Cognitive decline and dementia in diabetesâ€"systematic overview of prospective observational studies. Diabetologia, 2005, 48, 2460-2469.	2.9	852
20	nâ€"3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. New England Journal of Medicine, 2012, 367, 309-318.	13.9	810
21	Users' Guides to the Medical Literature. JAMA - Journal of the American Medical Association, 1994, 271, 389.	3.8	771
22	Myocardial Injury after Noncardiac Surgery. Anesthesiology, 2014, 120, 564-578.	1.3	740
23	Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Nonâ€"Q-Wave Myocardial Infarction. Circulation, 2000, 102, 1014-1019.	1.6	688
24	Effect of Ramipril on the Incidence of Diabetes. New England Journal of Medicine, 2006, 355, 1551-1562.	13.9	684
25	Users' Guides to the Medical Literature. JAMA - Journal of the American Medical Association, 1995, 274, 1800.	3.8	641
26	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. Circulation, 2007, 115, 114-126.	1.6	634
27	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care, 2007, 30, 162-172.	4.3	577
28	Users' Guides to the Medical Literature. JAMA - Journal of the American Medical Association, 1994, 272, 1367.	3.8	568
29	Users' Guides to the Medical Literature. JAMA - Journal of the American Medical Association, 1994, 271, 59.	3.8	527
30	Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. JAMA Cardiology, 2018, 3, 225.	3.0	526
31	Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods. American Journal of Cardiology, 2007, 99, S21-S33.	0.7	491
32	Ramipril and the Development of Diabetes. JAMA - Journal of the American Medical Association, 2001, 286, 1882.	3.8	487
33	Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: A systematic overview and meta-analysis of prospective studies. Diabetes Research and Clinical Practice, 2007, 78, 305-312.	1.1	471
34	Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurology, The, 2011, 10, 969-977.	4.9	455
35	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes and Endocrinology,the, 2021, 9, 653-662.	5.5	437
36	Effects of Cardiac Autonomic Dysfunction on Mortality Risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Diabetes Care, 2010, 33, 1578-1584.	4.3	435

#	Article	IF	Citations
37	A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3668-3676.	1.8	398
38	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet, The, 2019, 394, 131-138.	6.3	394
39	Relationship Between Baseline Glycemic Control and Cognitive Function in Individuals With Type 2 Diabetes and Other Cardiovascular Risk Factors. Diabetes Care, 2009, 32, 221-226.	4.3	387
40	Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes and Endocrinology,the, 2017, 5, 431-437.	5.5	379
41	The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ: British Medical Journal, 2010, 340, b5444-b5444.	2.4	359
42	Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes: Results of the HOPE Study and MICRO-HOPE Substudy. Diabetes Care, 2002, 25, 1919-1927.	4.3	349
43	Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. New England Journal of Medicine, 2021, 385, 896-907.	13.9	339
44	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditorsâ€™ Expert Forum. Diabetes Care, 2018, 41, 14-31.	4.3	338
45	Long-Term Consequences of Fetal and Neonatal Nicotine Exposure: A Critical Review. Toxicological Sciences, 2010, 116, 364-374.	1.4	307
46	Poor Cognitive Function and Risk of Severe Hypoglycemia in Type 2 Diabetes. Diabetes Care, 2012, 35, 787-793.	4.3	291
47	Association of Vitamin D With Insulin Resistance and Î²-Cell Dysfunction in Subjects at Risk for Type 2 Diabetes. Diabetes Care, 2010, 33, 1379-1381.	4.3	287
48	A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin. Diabetes Care, 2007, 30, 389-394.	4.3	280
49	Association Between Shortened Leukocyte Telomere Length and Cardiometabolic Outcomes. Circulation: Cardiovascular Genetics, 2015, 8, 82-90.	5.1	277
50	The Effect of Oral Antidiabetic Agents on A1C Levels. Diabetes Care, 2010, 33, 1859-1864.	4.3	275
51	Use of Inhaled Insulin in a Basal/Bolus Insulin Regimen in Type 1 Diabetic Subjects: A 6-month, randomized, comparative trial. Diabetes Care, 2005, 28, 1630-1635.	4.3	265
52	Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes and Endocrinology,the, 2014, 2, 843-851.	5.5	260
53	Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). Lancet, The, 2001, 358, 1147-1153.	6.3	257
54	Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease. Circulation, 2003, 108, 420-425.	1.6	257

#	Article	IF	Citations
55	Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nature Genetics, 2022, 54, 560-572.	9.4	250
56	Risk factors for acute myocardial infarction in Indians: a case-control study. Lancet, The, 1996, 348, 358-363.	6.3	246
57	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 877-886.	5.5	245
58	Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet, The, 2009, 374, 543-550.	6.3	239
59	Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation, 2006, 114, 201-208.	1.6	236
60	The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia, 2005, 48, 1749-1755.	2.9	233
61	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. Circulation, 2020, 142, 621-642.	1.6	232
62	The DREAM trial â€“ Authors' reply. Lancet, The, 2006, 368, 2050-2051.	6.3	230
63	Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial. Diabetes Care, 2014, 37, 1721-1728.	4.3	217
64	Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet, The, 2010, 376, 103-111.	6.3	216
65	Effects of Candesartan on the Development of a New Diagnosis of Diabetes Mellitus in Patients With Heart Failure. Circulation, 2005, 112, 48-53.	1.6	211
66	Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. European Heart Journal, 2013, 34, 3137-3144.	1.0	211
67	Does treatment withl-thyroxine influence health status in middle-aged and older adults with subclinical hypothyroidism?. Journal of General Internal Medicine, 1996, 11, 744-749.	1.3	205
68	Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. European Heart Journal, 2011, 32, 581-589.	1.0	199
69	Metabolic Syndrome and Risk of Acute Myocardial Infarction. Journal of the American College of Cardiology, 2010, 55, 2390-2398.	1.2	197
70	The Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients With Chronic Heart Failure. Archives of Internal Medicine, 2008, 168, 1699.	4.3	194
71	A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia) Tj ETQq1 1 0.784314 rgBT /Overlock	1.2	189
72	Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. American Journal of Cardiology, 2007, 99, S4-S20.	0.7	189

#	Article	IF	Citations
73	Computerized clinical decision support systems for chronic disease management: A decision-maker-researcher partnership systematic review. Implementation Science, 2011, 6, 92.	2.5	183
74	Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nature Metabolism, 2019, 1, 1202-1208.	5.1	181
75	Glucose Levels Predict Hospitalization for Congestive Heart Failure in Patients at High Cardiovascular Risk. Circulation, 2007, 115, 1371-1375.	1.6	180
76	Individualized electronic decision support and reminders to improve diabetes care in the community: COMPETE II randomized trial. Cmaj, 2009, 181, 37-44.	0.9	179
77	Kidney Disease After Preeclampsia: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2010, 55, 1026-1039.	2.1	177
78	Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.1	171
79	Dysglycaemia and risk of cardiovascular disease. Lancet, The, 1996, 347, 949-950.	6.3	164
80	Design and baseline characteristics of participants in the <scp>R</scp>esearching cardiovascular <scp>E</scp>vents with a <scp>W</scp>eekly <scp>IN</scp>cretin in <scp>D</scp>iabetes (<scp>REWIND</scp>) trial on the cardiovascular effects of dulaglutide. Diabetes, Obesity and Metabolism, 2018, 20, 42-49.	2.2	160
81	Does a Combination Regimen of Thyroxine (T4) and 3,5,3â€²-Triiodothyronine Improve Depressive Symptoms Better Than T4Alone in Patients with Hypothyroidism? Results of a Double-Blind, Randomized, Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4551-4555.	1.8	159
82	Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia, 2004, 47, 1519-1527.	2.9	157
83	Ethnic Variation in Adiponectin and Leptin Levels and Their Association With Adiposity and Insulin Resistance. Diabetes Care, 2010, 33, 1629-1634.	4.3	152
84	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care, 2021, 44, 2438-2444.	4.3	152
85	Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes. Diabetes Care, 2016, 39, 701-708.	4.3	150
86	Incidence of Postpartum Thyroid Dysfunction in Patients with Type I Diabetes Mellitus. Annals of Internal Medicine, 1993, 118, 419.	2.0	149
87	Glycemia Treatment Strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. American Journal of Cardiology, 2007, 99, S34-S43.	0.7	149
88	A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs. Diabetes Care, 2010, 33, 1176-1178.	4.3	145
89	The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureasâ€"a randomized trial. Diabetes Research and Clinical Practice, 2002, 55, 209-219.	1.1	144
90	Cognitive Function and Brain Structure in Persons With Type 2 Diabetes Mellitus After Intensive Lowering of Blood Pressure and Lipid Levels. JAMA Internal Medicine, 2014, 174, 324.	2.6	142

#	Article	IF	Citations
91	Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study. Diabetes Care, 2016, 39, 780-787.	4.3	138
92	Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 Diabetes. JAMA Cardiology, 2017, 2, 370.	3.0	136
93	Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet, The, 2014, 384, 1936-1941.	6.3	134
94	Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity. Biochemical Journal, 2015, 468, 125-132.	1.7	132
95	Development of Renal Disease in People at High Cardiovascular Risk: Results of the HOPE Randomized Study. Journal of the American Society of Nephrology: JASN, 2003, 14, 641-647.	3.0	130
96	Adipocyte Hypertrophy, Fatty Liver and Metabolic Risk Factors in South Asians: The Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE). PLoS ONE, 2011, 6, e22112.	1.1	128
97	Prospective Associations of Vitamin D With Î²-Cell Function and Glycemia. Diabetes, 2011, 60, 2947-2953.	0.3	124
98	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurology, The, 2020, 19, 582-590.	4.9	123
99	Differential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarction. Circulation, 2009, 120, 2429-2437.	1.6	121
100	Fetal and neonatal exposure to nicotine in Wistar rats results in increased beta cell apoptosis at birth and postnatal endocrine and metabolic changes associated with type 2 diabetes. Diabetologia, 2005, 48, 2661-2666.	2.9	120
101	Analysis of Health Utility Data When Some Subjects Attain the Upper Bound of 1: Are Tobit and CLAD Models Appropriate?. Value in Health, 2010, 13, 487-494.	0.1	120
102	Toward Fairness in Data Sharing. New England Journal of Medicine, 2016, 375, 405-407.	13.9	120
103	Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study. Diabetes Care, 2016, 39, 1089-1100.	4.3	119
104	Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. Lancet Diabetes and Endocrinology,the, 2018, 6, 798-808.	5.5	116
105	The protective effect of the obesity-associated rs9939609 A variant in fat mass- and obesity-associated gene on depression. Molecular Psychiatry, 2013, 18, 1281-1286.	4.1	115
106	Users' Guides to the Medical Literature. JAMA - Journal of the American Medical Association, 1995, 273, 1610.	3.8	114
107	Association of Depression With Accelerated Cognitive Decline Among Patients With Type 2 Diabetes in the ACCORD-MIND Trial. JAMA Psychiatry, 2013, 70, 1041.	6.0	114
108	Thyrocyte HLA-DR Expression and Interferon-Î³Production in Autoimmune Thyroid Disease*. Journal of Clinical Endocrinology and Metabolism, 1986, 63, 695-708.	1.8	113

#	Article	IF	Citations
109	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editorsâ€™ Expert Forum. Diabetes Care, 2016, 39, 1186-1201.	4.3	113
110	Growth Differentiation Factor 15 as a Novel Biomarker for Metformin. Diabetes Care, 2017, 40, 280-283.	4.3	112
111	Association of 25(OH)D and PTH with Metabolic Syndrome and Its Traditional and Nontraditional Components. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 168-175.	1.8	107
112	Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. European Heart Journal, 2015, 36, 1454-1462.	1.0	106
113	Effects of Randomization to Intensive Glucose Control on Adverse Events, Cardiovascular Disease, and Mortality in Older Versus Younger Adults in the ACCORD Trial. Diabetes Care, 2014, 37, 634-643.	4.3	104
114	Peripheral Neuropathy and Nerve Dysfunction in Individuals at High Risk for Type 2 Diabetes: The PROMISE Cohort. Diabetes Care, 2015, 38, 793-800.	4.3	104
115	Penetrance of Polygenic Obesity Susceptibility Loci across the Body Mass Index Distribution. American Journal of Human Genetics, 2017, 101, 925-938.	2.6	103
116	Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE Study. Kidney International, 2004, 65, 1375-1380.	2.6	102
117	Diabetes Risk Among Overweight and Obese Metabolically Healthy Young Adults. Diabetes Care, 2014, 37, 2989-2995.	4.3	100
118	Acarbose in the treatment of elderly patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2003, 59, 37-42.	1.1	97
119	Risk Prediction for Early CKD in Type 2 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1371-1379.	2.2	97
120	Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation, 2010, 121, 1176-1187.	1.6	95
121	The Economic Cost of Diabetes in Canada, 1998. Diabetes Care, 2002, 25, 1303-1307.	4.3	93
122	Relationship of epicardial fat thickness and fasting glucose. International Journal of Cardiology, 2008, 128, 424-426.	0.8	93
123	Serious Cardiovascular Outcomes in Diabetes. Circulation, 2011, 123, 342-348.	1.6	93
124	ACCORDION MIND: results of the observational extension of the ACCORD MIND randomised trial. Diabetologia, 2017, 60, 69-80.	2.9	93
125	Cardiometabolic Health in Adults Born Premature With Extremely Low Birth Weight. Pediatrics, 2016, 138, .	1.0	91
126	Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. Canadian Journal of Cardiology, 2010, 26, 297-302.	0.8	89

#	Article	IF	Citations
127	Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. Journal of the American College of Cardiology, 1999, 33, 612-619.	1.2	88
128	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. American Heart Journal, 2015, 169, 631-638.e7.	1.2	88
129	Diabetic Retinopathy, Its Progression, and Incident Cardiovascular Events in the ACCORD Trial. Diabetes Care, 2013, 36, 1266-1271.	4.3	86
130	Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. Kidney International, 2015, 87, 784-791.	2.6	86
131	Adolescent Obesity and Early-Onset Type 2 Diabetes. Diabetes Care, 2020, 43, 1487-1495.	4.3	84
132	Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: a systematic review. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1180-5.	1.4	83
133	Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: A subanalysis of the ORIGIN trial. International Journal of Cardiology, 2014, 174, 458-461.	0.8	83
134	Do sulphonylureas still have a place in clinical practice?. Lancet Diabetes and Endocrinology,the, 2018, 6, 821-832.	5.5	83
135	Maternal nicotine exposure increases oxidative stress in the offspring. Free Radical Biology and Medicine, 2008, 44, 1919-1925.	1.3	81
136	The Effect of Vitamin E Supplementation on Cardiovascular Risk in Diabetic Individuals With Different Haptoglobin Phenotypes. Diabetes Care, 2004, 27, 2767-2767.	4.3	78
137	Real-world studies no substitute for RCTs in establishing efficacy. Lancet, The, 2019, 393, 210-211.	6.3	78
138	Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respiratory Medicine, 2012, 106, 1487-1493.	1.3	77
139	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 106-114.	5.5	77
140	Troglitazone Monotherapy Improves Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled Study. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 3169-3176.	1.8	77
141	The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care, 2014, 37, 1360-1366.	4.3	76
142	Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. American Journal of Kidney Diseases, 2003, 42, 936-942.	2.1	75
143	Role of Bâ€Type Natriuretic Peptide and Nâ€Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2017, 6, .	1.6	75
144	Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. European Journal of Preventive Cardiology, 2012, 19, 755-764.	0.8	74

#	Article	IF	Citations
145	Fetal and neonatal nicotine exposure and postnatal glucose homeostasis: identifying critical windows of exposure. Journal of Endocrinology, 2007, 194, 171-178.	1.2	73
146	A Family-based Intervention to Promote Healthy Lifestyles in an Aboriginal Community in Canada. Canadian Journal of Public Health, 2007, 98, 447-452.	1.1	72
147	Dual inhibition of the reninâ€“angiotensin system in high-risk diabetes and risk for stroke and other outcomes. Journal of Hypertension, 2013, 31, 414-421.	0.3	72
148	Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes/Metabolism Research and Reviews, 2002, 18, S82-S85.	1.7	70
149	Diagnostic Strategies to Detect Glucose Intolerance in a Multiethnic Population. Diabetes Care, 2003, 26, 290-296.	4.3	70
150	Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney International, 2004, 66, S59-S62.	2.6	70
151	Association of Hematological Parameters with Insulin Resistance and Î²-Cell Dysfunction in Nondiabetic Subjects. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3824-3832.	1.8	69
152	BMI at Age 17 Years and Diabetes Mortality in Midlife: A Nationwide Cohort of 2.3 Million Adolescents. Diabetes Care, 2016, 39, 1996-2003.	4.3	69
153	Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease. Journal of the American College of Cardiology, 2018, 72, 300-310.	1.2	69
154	Spectrum of quality of life impairment in hypothyroidism. Quality of Life Research, 1994, 3, 323-327.	1.5	68
155	Fetal and Neonatal Nicotine Exposure in Wistar Rats Causes Progressive Pancreatic Mitochondrial Damage and Beta Cell Dysfunction. PLoS ONE, 2008, 3, e3371.	1.1	68
156	Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries. JAMA Internal Medicine, 2021, 181, 631.	2.6	68
157	Rationale and Design of a Large Study to Evaluate the Renal and Cardiovascular Effects of an ACE Inhibitor and Vitamin E in High-Risk Patients With Diabetes: The MICRO-HOPE Study. Diabetes Care, 1996, 19, 1225-1228.	4.3	67
158	Increased Pancreatic Beta-Cell Apoptosis following Fetal and Neonatal Exposure to Nicotine Is Mediated via the Mitochondria. Toxicological Sciences, 2008, 103, 362-370.	1.4	65
159	Establishing a relationship between prolactin and altered fatty acid Î²-Oxidation via carnitine palmitoyl transferase 1 in breast cancer cells. BMC Cancer, 2011, 11, 56.	1.1	65
160	Predictors of Nonsevere and Severe Hypoglycemia During Glucose-Lowering Treatment With Insulin Glargine or Standard Drugs in the ORIGIN Trial. Diabetes Care, 2015, 38, 22-28.	4.3	64
161	Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia. Circulation, 2015, 132, 2297-2304.	1.6	64
162	The Cross-sectional and Longitudinal Associations of Diabetic Retinopathy With Cognitive Function and Brain MRI Findings: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. Diabetes Care, 2014, 37, 3244-3252.	4.3	62

#	Article	IF	Citations
163	Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study. Scientific Reports, 2016, 6, 18672.	1.6	62
164	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. Circulation, 2020, 141, 843-862.	1.6	62
165	Cardiovascular risk in patients with mild renal insufficiency. Kidney International, 2003, 63, S192-S196.	2.6	61
166	Predictors of Development of Diabetes in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Diabetes Care, 2009, 32, 915-920.	4.3	61
167	Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial. European Heart Journal, 2020, 41, 2668-2677.	1.0	60
168	Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation, 2022, 145, 565-574.	1.6	59
169	Glycosylated Hemoglobin: Finally Ready for Prime Time as a Cardiovascular Risk Factor. Annals of Internal Medicine, 2004, 141, 475.	2.0	57
170	Causal Relationship between Adiponectin and Metabolic Traits: A Mendelian Randomization Study in a Multiethnic Population. PLoS ONE, 2013, 8, e66808.	1.1	57
171	Does Insulin Therapy Promote, Reduce, or Have a Neutral Effect on Cancers?. JAMA - Journal of the American Medical Association, 2010, 303, 446.	3.8	56
172	Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. Diabetologia, 2012, 55, 36-45.	2.9	56
173	Cognitive Function and the Risk for Diabetes Among Young Men. Diabetes Care, 2014, 37, 2982-2988.	4.3	56
174	Accumulation of Deficits as a Key Risk Factor for Cardiovascular Morbidity and Mortality: A Pooled Analysis of 154Â000 Individuals. Journal of the American Heart Association, 2020, 9, e014686.	1.6	56
175	Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Care, 2016, 39, 709-716.	4.3	55
176	Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample. Journal of Lipid Research, 2009, 50, 1487-1496.	2.0	54
177	Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. Journal of the American College of Cardiology, 2009, 53, 2028-2035.	1.2	54
178	Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: The Canadian INSIGHT Study. Diabetes Research and Clinical Practice, 2007, 78, 254-258.	1.1	53
179	Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney International, 2012, 81, 586-594.	2.6	53
180	Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a systematic review and meta-analysis with evidence from up to 331 175 individuals. Human Molecular Genetics, 2015, 24, 3582-3594.	1.4	53

#	Article	IF	Citations
181	Transgenerational effects of fetal and neonatal exposure to nicotine. Endocrine, 2007, 31, 254-259.	2.2	52
182	Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. Diabetologia, 2010, 53, 2509-2517.	2.9	52
183	Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. Lancet Diabetes and Endocrinology,the, 2014, 2, 562-572.	5.5	52
184	The Relationship Between Dysglycemia and Atherosclerosis in South Asian, Chinese, and European Individuals in Canada: A randomly sampled cross-sectional study. Diabetes Care, 2003, 26, 144-149.	4.3	51
185	Lack of Association Between Thiazolidinediones and Macular Edema in Type 2 Diabetes. JAMA Ophthalmology, 2010, 128, 312.	2.6	50
186	Effect of Rosiglitazone and Ramipril on Â-Cell Function in People With Impaired Glucose Tolerance or Impaired Fasting Glucose: The DREAM trial. Diabetes Care, 2010, 33, 608-613.	4.3	50
187	Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. American Heart Journal, 2014, 168, 23-29.e2.	1.2	50
188	Why don't pigs get diabetes? Explanations for variations in diabetes susceptibility in human populations living in a diabetogenic environment. Cmaj, 2006, 174, 25-26.	0.9	49
189	HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression. Diabetes Care, 2021, 44, 290-296.	4.3	49
190	Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes. Diabetologia, 2011, 54, 487-495.	2.9	48
191	Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia, 2014, 57, 1325-1331.	2.9	47
192	Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial. Diabetes Care, 2016, 39, 1915-1924.	4.3	47
193	Determinants of Weight Gain in the Action to Control Cardiovascular Risk in Diabetes Trial. Diabetes Care, 2013, 36, 2162-2168.	4.3	46
194	Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada. Quality of Life Research, 2011, 20, 939-943.	1.5	44
195	Prospective association of 25(<scp>OH</scp>)<scp>D</scp> with metabolic syndrome. Clinical Endocrinology, 2014, 80, 502-507.	1.2	44
196	Psychiatric Symptoms, Bone Density and Non-Specific Symptoms in Patients with Mild Hypercalcemia due to Primary Hyperparathyroidism: A Systematic Overview of the Literature.. Endocrine Journal, 1997, 44, 367-374.	0.7	43
197	A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks. Diabetes Care, 2018, 41, 1121-1124.	4.3	43
198	Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. Canadian Journal of Physiology and Pharmacology, 1999, 77, 118-123.	0.7	42

#	Article	IF	Citations
199	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. European Heart Journal, 2014, 35, 2242-2248.	1.0	42
200	White blood cell subtypes, insulin resistance and Î²â€cell dysfunction in highâ€risk individuals â€“ the PROMISE cohort. Clinical Endocrinology, 2014, 81, 536-541.	1.2	41
201	Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. Diabetic Medicine, 2010, 27, 175-180.	1.2	40
202	Do Lifestyle Changes Reduce Serious Outcomes in Diabetes?. New England Journal of Medicine, 2013, 369, 189-190.	13.9	40
203	Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events. Diabetes Care, 2013, 36, 2466-2474.	4.3	40
204	Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. Lancet Diabetes and Endocrinology,the, 2013, 1, 71-78.	5.5	39
205	Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetologia, 2021, 64, 2359-2366.	2.9	39
206	Enalapril prevents clinical proteinuria in diabetic patients with low ejection fraction. Diabetes Care, 2000, 23, 377-380.	4.3	38
207	Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1596-1605.	1.8	38
208	Sodiumâ€Glucose Coâ€Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Metaâ€Analysis of Randomized Controlled Trials. Journal of the American Heart Association, 2021, 10, e022222.	1.6	38
209	Shared Electronic Vascular Risk Decision Support in Primary Care. Archives of Internal Medicine, 2011, 171, 1736.	4.3	37
210	Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. International Journal of Clinical Practice, 2012, 66, 457-464.	0.8	37
211	Cognitive function in adolescence and the risk for premature diabetes and cardiovascular mortality in adulthood. Cardiovascular Diabetology, 2018, 17, 154.	2.7	37
212	Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia. Diabetes Research and Clinical Practice, 2007, 78, 392-397.	1.1	36
213	Generalizability of glucagonâ€like peptideâ€1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. Diabetes, Obesity and Metabolism, 2019, 21, 1299-1304.	2.2	36
214	Obesity Genes and Risk of Major Depressive Disorder in a Multiethnic Population. Journal of Clinical Psychiatry, 2015, 76, e1611-e1618.	1.1	36
215	Dysglycemia in a community sample of people treated for schizophrenia: The Diabetes in Schizophrenia in Central-south Ontario (DiSCO) study. Schizophrenia Research, 2007, 96, 215-222.	1.1	34
216	Variation at the NFATC2 Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study. Diabetes Care, 2010, 33, 2250-2253.	4.3	34

#	Article	IF	Citations
217	Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a subâ€study of the <scp>DREAM</scp> trial. Diabetic Medicine, 2014, 31, 1086-1092.	1.2	33
218	Lack of association between type 2 diabetes and major depression: epidemiologic and genetic evidence in a multiethnic population. Translational Psychiatry, 2015, 5, e618-e618.	2.4	32
219	Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial. Diabetes Care, 2018, 41, 2404-2413.	4.3	32
220	Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study. Diabetes Care, 2020, 43, 3094-3101.	4.3	32
221	Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1-9.	1.8	32
222	Effects of lifelong testosterone exposure on health and disease using Mendelian randomization. ELife, 2020, 9, .	2.8	32
223	A controlled evaluation of a national continuing medical education programme designed to improve family physicians' implementation of diabetes-specific clinical practice guidelines. Diabetic Medicine, 1999, 16, 964-969.	1.2	31
224	Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial. Diabetes Care, 2021, 44, 164-173.	4.3	31
225	Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial. Diabetologia, 2022, 65, 206-215.	2.9	31
226	Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care, 2022, 45, 684-691.	4.3	31
227	Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial. Diabetes, Obesity and Metabolism, 2006, 8, 531-537.	2.2	30
228	Incidence of Diabetes Following Ramipril or Rosiglitazone Withdrawal. Diabetes Care, 2011, 34, 1265-1269.	4.3	30
229	Hyperglycaemia is associated with impaired vasa vasorum neovascularization and accelerated atherosclerosis in apolipoprotein-E deficient mice. Atherosclerosis, 2013, 227, 250-258.	0.4	30
230	What accounts for ethnic differences in newborn skinfold thickness comparing South Asians and White Caucasians? Findings from the START and FAMILY Birth Cohorts. International Journal of Obesity, 2016, 40, 239-244.	1.6	30
231	Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization. Circulation, 2018, 137, 88-90.	1.6	30
232	How common is postpartum thyroiditis? A methodologic overview of the literature. Archives of Internal Medicine, 1990, 150, 1397-1400.	4.3	30
233	Cardiovascular Risk in Patients with Early Renal Insufficiency. American Journal of Cardiovascular Drugs, 2002, 2, 157-162.	1.0	29
234	Effects of rosiglitazone on ovarian function and fertility in animals with reduced fertility following fetal and neonatal exposure to nicotine. Endocrine, 2009, 36, 281-290.	1.1	29

#	Article	IF	Citations
235	Anthropometric measures and glucose levels in a large multi-ethnic cohort of individuals at risk of developing type 2 diabetes. Diabetologia, 2010, 53, 1322-1330.	2.9	29
236	More insights on the dysglycaemiaâ€“cardiovascular connection. Lancet, The, 2010, 375, 2195-2196.	6.3	29
237	Does genetic heterogeneity account for the divergent risk of type 2 diabetes in South Asian and white European populations?. Diabetologia, 2014, 57, 2270-2281.	2.9	29
238	Association Between Bariatric Surgery and Major Adverse Diabetes Outcomes in Patients With Diabetes and Obesity. JAMA Network Open, 2021, 4, e216820.	2.8	29
239	Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. Cardiovascular Diabetology, 2021, 20, 194.	2.7	29
240	The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators. Canadian Journal of Cardiology, 1998, 14, 1349-57.	0.8	29
241	Perceived exertion with glucose ingestion in adolescent males with IDDM. Medicine and Science in Sports and Exercise, 2000, 32, 167.	0.2	28
242	Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. American Heart Journal, 2009, 157, 763-770.	1.2	28
243	Causes and consequences of gestational diabetes in South Asians living in Canada: results from a prospective cohort study. CMAJ Open, 2017, 5, E604-E611.	1.1	28
244	PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. Diabetes, 2020, 69, 771-783.	0.3	28
245	ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study. Diabetes Care, 2020, 43, 835-842.	4.3	28
246	Determinants of cognitive function in individuals with type 2 diabetes mellitus: A meta-analysis. Annals of Clinical Psychiatry, 2018, 30, 38-50.	0.6	28
247	Effects of the dual peroxisome proliferatorâ€“activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes. American Heart Journal, 2015, 170, 117-122.	1.2	27
248	Maturation of CGM and Glycemic Measurements Beyond HbA1câ€”A Turning Point in Research and Clinical Decisions. Diabetes Care, 2017, 40, 1611-1613.	4.3	27
249	Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: Results from the ONTARGET/TRANSCEND Research Programme. Diabetes Research and Clinical Practice, 2009, 83, 387-393.	1.1	26
250	Short Leg Length, a Marker of Early Childhood Deprivation, Is Associated With Metabolic Disorders Underlying Type 2 Diabetes. Diabetes Care, 2013, 36, 3599-3606.	4.3	26
251	Dysglycaemia as a cause of cardiovascular outcomes. Nature Reviews Endocrinology, 2015, 11, 508-510.	4.3	26
252	Retinopathy, Neuropathy, and Subsequent Cardiovascular Events in Patients with Type 2 Diabetes and Acute Coronary Syndrome in the ELIXA: The Importance of Disease Duration. Journal of Diabetes Research, 2018, 2018, 1-9.	1.0	26

#	Article	IF	Citations
253	Can family physicians help patients initiate basal insulin therapy successfully?: randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. Canadian Family Physician, 2008, 54, 550-8.	0.1	26
254	Searching for answers to ethnic disparities in cardiovascular risk. Lancet, The, 2000, 356, 266-267.	6.3	25
255	Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies. European Heart Journal Supplements, 2003, 5, A43-A48.	0.0	25
256	Reevaluation by High-Performance Liquid Chromatography: Clinical Significance of Microalbuminuria in Individuals at High Risk of Cardiovascular Disease in the Heart Outcomes Prevention Evaluation (HOPE) Study. American Journal of Kidney Diseases, 2006, 48, 889-896.	2.1	25
257	Changes in trabecular bone microarchitecture in postmenopausal women with and without type 2 diabetes: a two year longitudinal study. BMC Musculoskeletal Disorders, 2013, 14, 114.	0.8	24
258	Association of preoperative glucose concentration with myocardial injury and death after non-cardiac surgery (GlucoVISION): a prospective cohort study. Lancet Diabetes and Endocrinology,the, 2018, 6, 790-797.	5.5	24
259	Rosiglitazone prevents diabetes by increasing betaâ€cell mass in an animal model of type 2 diabetes characterized by reduced betaâ€cell mass at birth. Diabetes, Obesity and Metabolism, 2008, 10, 763-771.	2.2	23
260	Dysglycemia and a History of Reproductive Risk Factors. Diabetes Care, 2008, 31, 1635-1638.	4.3	23
261	Dysglycemia and Cardiovascular Risk in the General Population. Circulation, 2009, 119, 773-775.	1.6	23
262	Relationship Between A1C and Fasting Plasma Glucose in Dysglycemia or Type 2 Diabetes: An analysis of baseline data from the ORIGIN trial. Diabetes Care, 2012, 35, 749-753.	4.3	23
263	Coronary artery disease risk among obese metabolically healthy young men. European Journal of Endocrinology, 2015, 173, 305-312.	1.9	23
264	Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood. Diabetes Care, 2020, 43, 145-151.	4.3	23
265	Genetic Information and the Prediction of Incident Type 2 Diabetes in a High-Risk Multiethnic Population. Diabetes Care, 2013, 36, 2836-2842.	4.3	22
266	Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A meta-analysis with the FREEDOM cardiovascular outcomes trial. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102382.	1.8	22
267	Increased occurrence of diabetes in people with ischemic cardiovascular disease and general and abdominal obesity. Canadian Journal of Cardiology, 2003, 19, 1387-91.	0.8	22
268	Insulin Therapy in People Who Have Dysglycemia and Type 2 Diabetes Mellitus: Can It Offer Both Cardiovascular Protection and Beta-Cell Preservation?. Endocrinology and Metabolism Clinics of North America, 2005, 34, 137-154.	1.2	21
269	Blood HER2 and Uromodulin as Causal Mediators of CKD. Journal of the American Society of Nephrology: JASN, 2018, 29, 1326-1335.	3.0	21
270	Identification of genetic effects underlying type 2 diabetes in South Asian and European populations. Communications Biology, 2022, 5, 329.	2.0	21

#	Article	IF	Citations
271	Clinical outcomes trials and the cardiovascular effects of thiazolidinediones: Implications for the evaluation of antidiabetic drugs. American Heart Journal, 2010, 160, 1-2.	1.2	20
272	Does a Patient-Managed Insulin Intensification Strategy With Insulin Glargine and Insulin Glulisine Provide Similar Glycemic Control as a Physician-Managed Strategy? Results of the START (Self-Titration) Tj ETQq0 0 0 rgBT /Overlock 10	4.3	20
273	Item reduction and validation of the Chinese version of diabetes quality-of-life measure (DQOL). Health and Quality of Life Outcomes, 2018, 16, 78.	1.0	20
274	Summary of Randomized Trials of Angiotensin Converting Enzyme Inhibitors. Clinical and Experimental Hypertension, 1999, 21, 835-845.	0.5	19
275	The HOPE study and diabetes. Lancet, The, 2000, 355, 1183-1184.	6.3	19
276	Miglitol, an Î±-glucosidase inhibitor, prevents the metformin-induced fall in serum folate and vitamin B12 in subjects with type 2 diabetes. Nutrition Research, 2000, 20, 1447-1456.	1.3	19
277	Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): Study design and baseline characteristics. American Heart Journal, 2008, 156, 1074-1079.	1.2	19
278	Telomere Length and Risk of Myocardial Infarction inÂa MultiEthnic Population. Journal of the American College of Cardiology, 2016, 67, 1863-1865.	1.2	19
279	Optimizing the methodology for measuring supraclavicular skin temperature using infrared thermography; implications for measuring brown adipose tissue activity in humans. Scientific Reports, 2017, 7, 11934.	1.6	19
280	Vascular Regenerative Cell Exhaustion in Diabetes: Translational Opportunities to Mitigate Cardiometabolic Risk. Trends in Molecular Medicine, 2019, 25, 640-655.	3.5	19
281	Dysglycemia and the Density of the Coronary Vasa Vasorum. Diabetes Care, 2019, 42, 980-982.	4.3	19
282	Influence of Genetic Ancestry on Human Serum Proteome. American Journal of Human Genetics, 2020, 106, 303-314.	2.6	19
283	Effect of Hypoglycemia on Brain Structure in People With Type 2 Diabetes: Epidemiological Analysis of the ACCORD-MIND MRI Trial. Diabetes Care, 2014, 37, 3279-3285.	4.3	18
284	Systolic Blood Pressure Control Among Individuals With Type 2 Diabetes: A Comparative Effectiveness Analysis of Three Interventions. American Journal of Hypertension, 2015, 28, 995-1009.	1.0	18
285	Antenatal exposure to the selective serotonin reuptake inhibitor fluoxetine leads to postnatal metabolic and endocrine changes associated with type 2 diabetes in Wistar rats. Toxicology and Applied Pharmacology, 2015, 285, 32-40.	1.3	18
286	Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial. Diabetes Care, 2019, 42, 142-147.	4.3	18
287	Remission of Type 2 Diabetes Following a Short-term Intervention With Insulin Glargine, Metformin, and Dapagliflozin. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2532-2540.	1.8	18
288	Obesity in late adolescence and incident type 1 diabetes in young adulthood. Diabetologia, 2022, 65, 1473-1482.	2.9	18

#	Article	IF	Citations
289	Dysglycemia: A Key Cardiovascular Risk Factor. Seminars in Vascular Medicine, 2002, 2, 165-174.	2.1	17
290	Cognitive Performance at Late Adolescence and the Risk for Impaired Fasting Glucose Among Young Adults. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4409-4416.	1.8	17
291	Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. American Journal of Medicine, 2017, 130, 1465.e27-1465.e39.	0.6	17
292	Are large simple trials for dementia prevention possible?. Age and Ageing, 2020, 49, 154-160.	0.7	17
293	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. European Heart Journal, 2021, 42, 2565-2573.	1.0	17
294	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 484-490.	5.5	17
295	Maternal antioxidants prevent Î²â€cell apoptosis and promote formation of dual hormoneâ€expressing endocrine cells in male offspring following fetal and neonatal nicotine exposure. Journal of Diabetes, 2012, 4, 297-306.	0.8	16
296	Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD. Diabetes Care, 2018, 41, 348-355.	4.3	16
297	A Mendelian Randomization-Based Approach to Identify Early and Sensitive Diagnostic Biomarkers of Disease. Clinical Chemistry, 2019, 65, 427-436.	1.5	16
298	Hyperglycaemia, ejection fraction and the risk of heart failure or cardiovascular death in patients with type 2 diabetes and a recent acute coronary syndrome. European Journal of Heart Failure, 2020, 22, 1133-1143.	2.9	16
299	Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study. European Journal of Preventive Cardiology, 2022, 29, 1334-1342.	0.8	16
300	Dysglycemia, not just diabetes, is a continuous risk factor for cardiovascular disease. Evidence-based Cardiovascular Medicine, 1997, 1, 87-88.	0.0	15
301	Point: If It Is Important to Prevent Type 2 Diabetes, It Is Important to Consider All Proven Therapies Within a Comprehensive Approach. Diabetes Care, 2007, 30, 432-434.	4.3	15
302	Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetic Medicine, 2010, 27, 1226-1232.	1.2	15
303	Glycemic Index Predicts Individual Glucose Responses after Self-Selected Breakfasts in Free-Living, Abdominally Obese Adults. Journal of Nutrition, 2012, 142, 27-32.	1.3	15
304	Piloting a Novel Algorithm for Glucose Control in the Coronary Care Unit. Diabetes Care, 2012, 35, 19-24.	4.3	15
305	Sleep quality and risk of diabetes and coronary artery disease among young men. Acta Diabetologica, 2016, 53, 261-270.	1.2	15
306	Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus. Circulation, 2017, 136, 1560-1562.	1.6	15

#	Article	IF	Citations
307	The Genetic Link Between Diabetes and Atherosclerosis. Canadian Journal of Cardiology, 2018, 34, 565-574.	0.8	15
308	Consensus report: Definition and interpretation of remission in type 2 diabetes. Diabetic Medicine, 2022, 39, e14669.	1.2	15
309	Dysglycaemia: a cardiovascular risk factor. Diabetes Research and Clinical Practice, 1998, 40, S9-S14.	1.1	14
310	Can community retail pharmacist and diabetes expert support facilitate insulin initiation by family physicians? Results of the AIM@GP randomized controlled trial. BMC Health Services Research, 2013, 13, 71.	0.9	14
311	Increased cardiovascular risk after preâ€eclampsia in women with dysglycaemia. Diabetic Medicine, 2013, 30, e1-7.	1.2	14
312	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovascular Diabetology, 2020, 19, 199.	2.7	14
313	Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1345-1351.	1.8	14
314	Randomized trial of insulin versus usual care in reducing restenosis after coronary intervention in patients with diabetes. the STent Restenosis And Metabolism (STREAM) study. Cardiovascular Revascularization Medicine, 2012, 13, 95-100.	0.3	13
315	Cost implications of the use of basal insulin glargine in people with early dysglycemia: The ORIGIN trial. Journal of Diabetes and Its Complications, 2014, 28, 553-558.	1.2	13
316	Comment on Hempe et al. The Hemoglobin Glycation Index Identifies Subpopulations With Harms or Benefits From Intensive Treatment in the ACCORD Trial. Diabetes Care 2015;38:1067â€“1074. Diabetes Care, 2015, 38, e170-e171.	4.3	13
317	Systematic review: Can non-mydriatic cameras accurately detect diabetic retinopathy?. Diabetes Research and Clinical Practice, 2017, 129, 154-159.	1.1	13
318	Validation of the ORIGIN Cardiovascular Biomarker Panel and the Value of Adding Troponin I in Dysglycemic People. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2251-2257.	1.8	13
319	The Cardiovascular Legacy of Good Glycemic Control: Clues About Mediators From the DCCT/EDIC Study. Diabetes Care, 2019, 42, 1159-1161.	4.3	13
320	Effect of Diabetes Health Coaching on Glycemic Control and Quality of Life in Adults Living With Type 2 Diabetes: A Community-Based, Randomized, Controlled Trial. Canadian Journal of Diabetes, 2021, 45, 594-600.	0.4	13
321	Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e34-e44.	1.8	13
322	A New Mutation in the Thyroid Hormone Receptor (TR) Î² Gene (V458A) in a Family with Resistance to Thyroid Hormone (RTH). Thyroid, 1996, 6, 311-312.	2.4	12
323	Effect of Computer-Generated Tailored Feedback on Glycemic Control in People With Diabetes in the Community. Diabetes Care, 2011, 34, 1794-1798.	4.3	12
324	Basal Insulin and Cardiovascular and Other Outcomes. New England Journal of Medicine, 2012, 367, 1761-1764.	13.9	12

#	Article	IF	Citations
325	Identification of Novel Causal Blood Biomarkers Linking Metabolically Favorable Adiposity With Type 2 Diabetes Risk. Diabetes Care, 2019, 42, 1800-1808.	4.3	12
326	Design and baseline characteristics of the <scp>AMPLITUDEâ€Œ</scp> cardiovascular outcomes trial of efpeglenatide, a weekly glucagonâ€like peptideâ€1 receptor agonist. Diabetes, Obesity and Metabolism, 2021, 23, 318-323.	2.2	12
327	Glucose Intolerance in Pregnancy and Offspring Obesity in Late Adolescence. Diabetes Care, 2022, 45, 1540-1548.	4.3	12
328	Is regression to normoglycaemia clinically important?. Lancet, The, 2012, 379, 2216-2218.	6.3	11
329	Postnatal Metabolic and Reproductive Consequences of Fetal and Neonatal Exposure to the Smoking Cessation Drug Bupropion. Reproductive Sciences, 2013, 20, 1156-1161.	1.1	11
330	Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trial. European Journal of Preventive Cardiology, 2019, 26, 847-854.	0.8	11
331	Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. Diabetes Care, 2020, 43, 2242-2247.	4.3	11
332	Diabetes, Brain Infarcts, Cognition, and Small Vessels in the Canadian Alliance for Healthy Hearts and Minds Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e891-e898.	1.8	11
333	Separate Induction of MHC and Thyroid Microsomal Antigen (McAg) Expression on Thyroid Cell Monolayers: Enhancement of Lectin-Induced McAg Expression by Interferon-Î³*. Journal of Clinical Endocrinology and Metabolism, 1987, 64, 1302-1308.	1.8	10
334	Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial. Diabetic Medicine, 2004, 21, 1200-1203.	1.2	10
335	Is it possible to reduce cardiovascular risk with glucose-lowering approaches?. Nature Reviews Endocrinology, 2009, 5, 270-275.	4.3	10
336	Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial. Diabetologia, 2014, 57, 2030-2037.	2.9	10
337	Insulin resistance and cardiovascular outcomes in the <scp>ORIGIN</scp> trial. Diabetes, Obesity and Metabolism, 2018, 20, 564-570.	2.2	10
338	Insulin Therapy: The Discovery That Shaped a Century. Canadian Journal of Diabetes, 2021, , .	0.4	10
339	Preventive medicine in a diabetes clinic: an opportunity to make a difference. Lancet, The, 1999, 353, 606-608.	6.3	9
340	Dosage Recommendations for Combination Regimen of Thyroxine and 3,5,3â€²-Triiodothyronine. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1486-1487.	1.8	9
341	Impact of a computerized system for evidence-based diabetes care on completeness of records: a beforeâ€“after study. BMC Medical Informatics and Decision Making, 2012, 12, 63.	1.5	9
342	Evaluating the Feasibility and Impact of an Internet-Based Lifestyle Management Program in a Diabetes Care Setting. Diabetes Technology and Therapeutics, 2014, 16, 358-362.	2.4	9

#	Article	IF	Citations
343	Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI. Diabetologia, 2014, 57, 738-745.	2.9	9
344	The Relationship Between Glucose Control and Cognitive Function in People With Diabetes After a Lacunar Stroke. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1521-1528.	1.8	9
345	Epidemiologic analyses of risk factors, risk indicators, risk markers, and causal factors. Endocrinology and Metabolism Clinics of North America, 2002, 31, 537-551.	1.2	8
346	The effects of exercise training on insulin resistance in patients with coronary artery disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2007, 14, 803-808.	3.1	8
347	Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points. Diabetes and Vascular Disease Research, 2008, 5, 276-284.	0.9	8
348	Metabolic effects of telmisartan in subjects with abdominal obesity: A prospective randomized controlled trial. Blood Pressure, 2014, 23, 54-60.	0.7	8
349	The Relationship between Intramuscular Adipose Tissue, Functional Mobility, and Strength in Postmenopausal Women with and without Type 2 Diabetes. Journal of Aging Research, 2015, 2015, 1-9.	0.4	8
350	The Relationship Between the Score on a Simple Measure of Cognitive Function and Incident CVD in People With Diabetes: A Post Hoc Epidemiological Analysis From the ACCORD-MIND Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3218-3225.	1.8	8
351	Novel Biomarkers for Change in Renal Function in People With Dysglycemia. Diabetes Care, 2020, 43, 433-439.	4.3	8
352	Identification of Circulating Proteins Associated With Blood Pressure Using Mendelian Randomization. Circulation Genomic and Precision Medicine, 2020, 13, e002605.	1.6	8
353	Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents. Diabetes Care, 2021, 44, e6-e8.	4.3	8
354	Creating Composite Indices From Continuous Variables for Research: The Geometric Mean. Diabetes Care, 2021, 44, e85-e86.	4.3	8
355	Shortâ€term intensive insulin as induction and maintenance therapy for the preservation of betaâ€cell function in early type 2 diabetes (<scp>RESETâ€IT Main</scp>): A 2â€year randomized controlled trial. Diabetes, Obesity and Metabolism, 2021, 23, 1926-1935.	2.2	8
356	Adolescent Thyroid Disorders and Risk for Type 2 Diabetes in Young Adulthood. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3426-e3435.	1.8	8
357	Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial. Diabetes Care, 2022, 45, 178-185.	4.3	8
358	Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2682-2689.	1.8	7
359	Newly diagnosed type 2 diabetes may serve as a potential marker for pancreatic cancer. Diabetes/Metabolism Research and Reviews, 2018, 34, e3018.	1.7	7
360	The importance of randomised vs non-randomised trials â€“ Authors' reply. Lancet, The, 2019, 394, 635.	6.3	7

#	Article	IF	Citations
361	The Diabetes Health Coaching Randomized Controlled Trial: Rationale, Design and Baseline Characteristics of Adults Living With Type 2 Diabetes. Canadian Journal of Diabetes, 2019, 43, 477-482.	0.4	7
362	Sensitization of T lymphocytes to thyroid antigen in autoimmune thyroid disease as demonstrated by the monocyte procoagulant activity test. Journal of Endocrinological Investigation, 1986, 9, 471-478.	1.8	6
363	Rosiglitazone improves pancreatic mitochondrial function in an animal model of dysglycemia: role of the insulin-like growth factor axis. Endocrine, 2010, 37, 303-311.	1.1	6
364	Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population. Journal of Diabetes, 2011, 3, 232-237.	0.8	6
365	Testosterone and sex hormone-binding globulin in dysglycemic women at high cardiovascular risk: A report from the Outcome Reduction with an Initial Glargine Intervention trial. Diabetes and Vascular Disease Research, 2021, 18, 147916412110024.	0.9	6
366	Cardiovascular Outcomes and Renal Disease. Annals of Internal Medicine, 2002, 136, 634.	2.0	5
367	Dysglycaemia, dyslipidaemia and hypertension: risk factors primarily focused on the disease or risk estimates primarily focused on the patient?. Diabetologia, 2011, 54, 230-232.	2.9	5
368	Longitudinal relationships between glycemic status and body mass index in a multiethnic study: evidence from observational and genetic epidemiology. Scientific Reports, 2016, 6, 30744.	1.6	5
369	Influence of depression on genetic predisposition to type 2 diabetes in a multiethnic longitudinal study. Scientific Reports, 2017, 7, 1629.	1.6	5
370	Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants. American Heart Journal, 2018, 199, 170-175.	1.2	5
371	Cardiovascular Outcomes Trials of Glucose-Lowering Drugs or Strategies in Type 2 Diabetes. Endocrinology and Metabolism Clinics of North America, 2018, 47, 97-116.	1.2	5
372	The association of basal insulin treatment versus standard care with outcomes in antiâ€GAD positive and negative subjects: A postâ€hoc analysis of the ORIGIN trial. Diabetes, Obesity and Metabolism, 2019, 21, 429-433.	2.2	5
373	Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes. Journal of the American Heart Association, 2022, 11, e021327.	1.6	5
374	The Burden of Treatment Failure in Type 2 Diabetes: Response to Brown et al.. Diabetes Care, 2005, 28, 761-762.	4.3	4
375	Self-Perceived Emotional Distress and Diabetes Risk Among Young Men. American Journal of Preventive Medicine, 2016, 50, 737-745.	1.6	4
376	Minimally important difference and predictors of change in quality of life in type 2 diabetes: A communityâ€based survey in China. Diabetes/Metabolism Research and Reviews, 2018, 34, e3053.	1.7	4
377	Stuttering and Incident Type 2 Diabetes: A Population-Based Study of 2.2 Million Adolescents. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e978-e987.	1.8	4
378	Adolescent cognitive function and incident early-onset type 2 diabetes. EClinicalMedicine, 2021, 41, 101138.	3.2	4

#	Article	IF	Citations
379	The Plasma Glucose Level - A Continuous Risk Factor for Vascular Disease in Both Diabetic and Non-Diabetic People. Advances in Experimental Medicine and Biology, 2001, 498, 35-39.	0.8	4
380	Lingering Effects of Hyperglycemia in Recently Diagnosed Diabetes During Long-term Follow-up of the DCCT/EDIC and UKPDS Cohorts: More Evidence That Early Control Matters. Diabetes Care, 2021, 44, 2212-2215.	4.3	4
381	Individualized electronic decision support and reminders can improve diabetes care in the community. AMIA ... Annual Symposium proceedings, 2005, , 982.	0.2	4
382	Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the <scp>REWIND</scp> randomized trial. Diabetes, Obesity and Metabolism, 2022, 24, 704-712.	2.2	4
383	HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial. Diabetes Care, 2022, , .	4.3	4
384	Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to <scp>iGlarLixi</scp> in the <scp>LixiLan ONE CAN</scp> randomized trial. Diabetes, Obesity and Metabolism, 2022, 24, 1998-2007.	2.2	4
385	Effect of combining rosiglitazone with either metformin or insulin on Î²-cell mass and function in an animal model of Type 2 diabetes characterized by reduced Î²-cell mass at birth. Journal of Diabetes, 2011, 3, 74-81.	0.8	3
386	The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial. Diabetes and Vascular Disease Research, 2017, 14, 345-352.	0.9	3
387	Effects of basal insulin glargine and omegaâ€3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial. Diabetes, Obesity and Metabolism, 2019, 21, 1502-1505.	2.2	3
388	Myopia and Early-Onset Type 2 Diabetes: A Nationwide Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e663-e671.	1.8	3
389	Protein Biomarkers and Cardiovascular Outcomes in People With Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study. Diabetes Care, 2022, 45, 2152-2155.	4.3	3
390	IMMUNOMODULATORY EFFECT OF THE TREATMENT OF GRAVESâ€™DISEASE ON ANTIGEN-SPECIFIC MONOCYTE PROCOAGULANT ACTIVITY PRODUCTION. Clinical Endocrinology, 1987, 27, 321-330.	1.2	2
391	A disturbed glucose metabolic state (dysglycaemia) is a key risk factor for cardiovascular events. European Heart Journal Supplements, 2003, 5, B1-B2.	0.0	2
392	Does pioglitazone prevent macrovascular events in patients with type 2 diabetes?. Cmaj, 2006, 174, 1090-1091.	0.9	2
393	Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 798-799.	2.9	2
394	Setting the record straight on TIDE: a lost opportunity for patients with diabetes. Diabetologia, 2013, 56, 1884-1887.	2.9	2
395	Rosiglitazone and Cardiovascular Outcomes. Circulation, 2013, 128, 777-779.	1.6	2
396	Willingness to take drugs to prevent serious chronic diseases (è‡ªæ„¿æœç”¨è¯ç‰©»ä»¥é¢„é˜²ä¸¥é‡ç–¾ç—…...). Journal of Di	2	

#	Article	IF	Citations
397	Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug Response. Frontiers in Genetics, 2016, 7, 138.	1.1	2
398	The obesity paradigm in cardiovascular disease: the need for differentiated weight management. European Heart Journal, 2020, 41, 3965-3965.	1.0	2
399	Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trials. Lancet Diabetes and Endocrinology,the, 2020, 8, 557-558.	5.5	2
400	Asthma in Youth and Early-onset Type 2 Diabetes: A Nationwide Study of 1.72 Million Israeli Adolescents. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e5043-e5053.	1.8	2
401	NT-proBNP versus routine clinical risk factors as a predictor of cardiovascular events or death in people with dysglycemia â€“ A brief report from the ORIGIN trial. Journal of Diabetes and Its Complications, 2021, 35, 107928.	1.2	2
402	Neighborhood Walkability and Diabetes-Related Complications. Diabetes, 2018, 67, 309-OR.	0.3	2
403	356-OR: Effect of Dulaglutide on Kidney Functionâ€“Related Outcomes in Type 2 Diabetes: Post Hoc Analysis from the REWIND Trial. Diabetes, 2020, 69, 356-OR.	0.3	2
404	Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3448-e3454.	1.8	2
405	Efficacy and safety outcomes of dulaglutide by baseline <scp>HbA1c</scp>: A post hoc analysis of the <scp>REWIND</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 1753-1761.	2.2	2
406	Association of Eligibility for a Sodium-Glucose Cotransporter 2 Inhibitor and Cardiovascular Events in Patients With Atrial Fibrillation. Canadian Journal of Cardiology, 2022, 38, 1434-1441.	0.8	2
407	Shouldnâ€™t Preventing Type 2 Diabetes Also Prevent Its Long-Term Consequences?. Circulation, 2022, 145, 1642-1644.	1.6	2
408	The value of large, robust trials: the HOPE study. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2002, 19, 29-30.	0.2	1
409	Authorsâ€™ Response: Dosage Recommendations for Combination Regimen of Thyroxine and 3,5,3â€²-Triiodothyronine. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1487-1487.	1.8	1
410	Reply to comment on: Gerstein HC, Pogue J, Mann JFE et al. (2005) The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia 48:1749â€“1755. Diabetologia, 2006, 49, 613-614.	2.9	1
411	Low-Dose Combination Therapy With Rosiglitazone And Metformin to Prevent Type 2 Diabetes Mellitus (CANOE Trial): A Double-Blind Randomized Controlled Study. Obstetrical and Gynecological Survey, 2010, 65, 771-772.	0.2	1
412	A community-based approach for the self-management of diabetes. European Diabetes Nursing, 2011, 8, 54-59.	0.2	1
413	Long-Acting Risperidone and Oral Antipsychotics in Schizophrenia. New England Journal of Medicine, 2011, 364, 2264-2266.	13.9	1
414	Response to Comment on: The ORIGIN Trial Investigators. Characteristics Associated With Maintenance of Mean A1C <6.5% in People With Dysglycemia in the ORIGIN Trial. Diabetes Care 2013;36:2915-2922. Diabetes Care, 2013, 36, e181-e181.	4.3	1

#	Article	IF	Citations
415	Response to Suissa and Azoulay. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360â€“1366. Diabetes Care, 2014, 37, e217-e217.	4.3	1
416	Writing science that your colleagues can read. Journal of Diabetes and Its Complications, 2014, 28, 4-5.	1.2	1
417	Making a Difference With Diabetes Research and Care: Table 1. Diabetes Care, 2016, 39, 1309-1310.	4.3	1
418	Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editorsâ€™ Expert Forum. Diabetes Care 2016;39:1186â€“1201. Diabetes Care, 2017, 40, e23-e24.	4.3	1
419	Exploring the Experiences of Adults With Type 2 Diabetes on Sodium Glucose Cotransporter 2 Inhibitors. Canadian Journal of Diabetes, 2020, 44, 184-191.	0.4	1
420	Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. Cardiovascular Diabetology, 2020, 19, 175.	2.7	1
421	Economic analysis of a diabetes health coaching intervention for adults living with type 2 diabetes. A single centre evaluation from a community-based randomized controlled trial.. Canadian Journal of Diabetes, 2021, , .	0.4	1
422	924-P: Exploring Potential Mediators of the Cardiovascular Benefit of Dulaglutide in REWIND. Diabetes, 2020, 69, 924-P.	0.3	1
423	944-P: HbA1c Change Is Associated with Retinopathy Outcomes during GLP-1RA CVOT Follow-Up. Diabetes, 2020, 69, .	0.3	1
424	Prevention of the Consequences of Diabetes- a Commentary. , 0, , 266-272.		1
425	Ramipril slowed the decline in renal function among patients with nephropathy and proteinuria not due to insulin-dependent diabetes mellitus. Evidence-based Cardiovascular Medicine, 1998, 2, 23-24.	0.0	0
426	Reducing the Risk of Cardiovascular Complications in the Long-Term Care Setting. Journal of the American Medical Directors Association, 2001, 2, H13-H16.	1.2	0
427	Diabetes susceptibility. Cmaj, 2006, 174, 1598-1598.	0.9	0
428	Response to Letter Regarding Article, â€œDifferential Clinical Outcomes Associated With Hypoglycemia and Hyperglycemia in Acute Myocardial Infarctionâ€• Circulation, 2010, 122, .	1.6	0
429	Macular Edema and Thiazolidinedionesâ€”Reply. JAMA Ophthalmology, 2010, 128, 1631.	2.6	0
430	Response to Zanders et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360â€“1366. Diabetes Care, 2014, 37, e223-e223.	4.3	0
431	Effects of intensive glycaemic control on ischaemic heart disease â€“ Authors' reply. Lancet, The, 2015, 385, 1180-1181.	6.3	0
432	Microvascular outcomes in type 2 diabetes â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2017, 5, 580.	5.5	0

#	Article	IF	Citations
433	Effect of insulin glargine on recreational physical activity and TV viewing: Analysis of the randomised ORIGIN trial. Diabetes Research and Clinical Practice, 2017, 132, 137-143.	1.1	0
434	In high-risk T1DM, real-time continuous glucose monitoring vs self-monitoring reduced hypoglycemic events. Annals of Internal Medicine, 2018, 168, JC53.	2.0	0
435	Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics. EndocrinologÃa Diabetes Y NutriciÃ³n (English Ed), 2019, 66, 467-468.	0.1	0
436	Insulin use for type 2 diabetes: the challenges of predicting trends and modelling care. Lancet Diabetes and Endocrinology,the, 2019, 7, 4-5.	5.5	0
437	DULAGLUTIDE REDUCES HBA1C IRRESPECTIVE OF ANTIHYPERGLYCEMIC AGENTS, DURATION OF DIABETES, BMI AND WEIGHT LOSS: A POST HOC ANALYSIS FROM THE REWIND TRIAL. Journal of the American College of Cardiology, 2020, 75, 1951.	1.2	0
438	Dulaglutide slows kidney disease in type 2 diabetes â^' Author's reply. Lancet, The, 2020, 395, 559-560.	6.3	0
439	95-LB: LixilanONE CAN: Randomized Trial Comparing a Daily vs. Weekly Titration Algorithm for Switching from Basal Insulin to iGlarLixi Fixed-Ratio Combination in People with T2DM in Canada. Diabetes, 2021, 70, 95-LB.	0.3	0
440	677-P: Remission of Type 2 Diabetes following Intensive Treatment with Insulin Glargine, Lixisenatide, Metformin, and Lifestyle Approaches: Results of a Multicenter Randomized Controlled Trial. Diabetes, 2021, 70, 677-P.	0.3	0
441	187-OR: Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes in the ACCORD Trial. Diabetes, 2021, 70, .	0.3	0
442	Glycemia and Risk for Cardiovascular Disease. Annals of Internal Medicine, 2005, 142, 227.	2.0	0
443	240-LB: Angiotensin-Converting Enzyme and Type 2 Diabetes Risk: A Mendelian Randomization Study. Diabetes, 2019, 68, 240-LB.	0.3	0
444	1506-P: Breast Cancer as a Risk Factor for New Diabetes. Diabetes, 2019, 68, .	0.3	0
445	254-OR: Novel Biomarkers Predicting Renal Dysfunction in People with Dysglycemia in the ORIGIN Trial. Diabetes, 2019, 68, .	0.3	0
446	Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics. Endocrinologia, Diabetes Y NutriciÃ“n, 2019, 66, 467-468.	0.1	0
447	130-OR: Effects of Intensive Risk Factor Management on Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: Findings from the ACCORD Trial. Diabetes, 2020, 69, 130-OR.	0.3	0
448	1421-P: The Impact of Blood Pressure on Risk of Death Is Influenced by Prior Cardiovascular Disease in Patients with Type 2 Diabetes and a Recent Coronary Event. Diabetes, 2020, 69, .	0.3	0
449	Enalapril reduced the risk for developing new-onset diabetes in left ventricular dysfunction. ACP Journal Club, 2003, 139, 68.	0.1	0
450	Intensive insulin therapy reduced cardiovascular disease in type 1 diabetes. ACP Journal Club, 2006, 144, 63.	0.1	0

#	Article	IF	Citations
451	Biomarkers of Prevalent and Incident Cognitive Dysfunction in People with Dysglycemia- Data from the ORIGIN Trial. Journal of Alzheimer's Disease, 2022, , 1-8.	1.2	0
452	Response to Comment on Koska et al. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care 2022;44:684â€“691. Diabetes Care, 2022, 45, e111-e112.	4.3	0
453	Lixilan ONE CAN: Randomisierte Studie zum Vergleich eines tÃglichen vs. wÃ¶chentlichen Titrationsalgorithmus fÃ¼r den Wechsel von Basalinsulin zur Fixkombination iGlarLixi bei Typ-2-Diabetespatienten in Kanada. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0
454	Response by Lam and Gerstein to Letter Regarding Article, â€œEfpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trialâ€. Circulation, 2022, 146, .	1.6	0